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Abstract
Mitotic regulators exhibiting gain of function in tumor cells are considered useful cancer therapeutic targets for the
development of small-molecule inhibitors. The human Aurora kinases are a family of such targets. In this study, from a panel
of 105 potential small-molecule inhibitors, two compounds Tripolin A and Tripolin B, inhibited Aurora A kinase activity in
vitro. In human cells however, only Tripolin A acted as an Aurora A inhibitor. We combined in vitro, in vivo single cell and in
silico studies to demonstrate the biological action of Tripolin A, a non-ATP competitive inhibitor. Tripolin A reduced the
localization of pAurora A on spindle microtubules (MTs), affected centrosome integrity, spindle formation and length, as
well as MT dynamics in interphase, consistent with Aurora A inhibition by RNAi or other specific inhibitors, such as MLN8054
or MLN8237. Interestingly, Tripolin A affected the gradient distribution towards the chromosomes, but not the MT binding
of HURP (Hepatoma Up-Regulated Protein), a MT-associated protein (MAP) and substrate of the Aurora A kinase. Therefore
Tripolin A reveals a new way of regulating mitotic MT stabilizers through Aurora A phosphorylation. Tripolin A is predicted
to bind Aurora A similarly but not identical to MLN8054, therefore it could be used to dissect pathways orchestrated by
Aurora kinases as well as a scaffold for further inhibitor development.
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Introduction
Temporal and spatial coordination of the process of mitosis and
cytokinesis is a prerequisite for accurate and equal segregation of
genomic and cytosolic material into two daughter cells. Among the
network of regulatory proteins, Aurora kinases are of particular
importance. In terms of enzymatic activity, Aurora kinases belong
to the Ser/Thr kinase family and they comprise of two domains: a
regulatory domain at the NH2-terminus and a catalytic domain at
the COOH-terminus. Auroras share a great degree of homology
in their catalytic domain, whereas differ in their NH2-terminal
domain. The mammalian orthologs are at least three: Aurora A,
Aurora B and Aurora C [1].
By means of phosphorylating different substrates, including
TPX2 [2], Ajuba [3], TACC3 [4,5], Eg5 [6] and HURP [7,8]
among others, Aurora A is implicated in diverse cell cycle events:
centrosome maturation and separation, mitotic entry, bipolar
spindle assembly, chromosome alignment, spindle checkpoint and
cytokinesis. TPX2 is not merely a substrate but also the best-
studied activator of Aurora A, required for Aurora A localization
to spindles [2]. Moreover, Aurora A regulates the mitotic spindle
apparatus in Xenopus as part of a multi-protein complex along with
the kinesin Eg5 and three MAPs; TPX2, XMAP215 and HURP
[9]. HURP is a MT stabilizer with distinct features since it
localizes mainly to kinetochore MTs (kt-MTs) of the mitotic
spindle [9,10] and induces a unique MT conformation in vitro [11].
Previous studies suggested a regulatory mechanism where
phosphorylation of HURP by Aurora A controls its MT binding
[8,12].
Aurora A is frequently amplified and/or over-expressed in
diverse tumor types [13], while over-expression of Aurora A is
associated with aneuploidy, centrosomal abnormalities [14,15]
and linked to chromosomal instability [16], features that play key
roles in tumor progression. Cells that overexpress Aurora A exhibit
substantial resistance to Taxol-induced apoptosis, a common MT
targeted chemotherapeutic drug [17].
Small-molecule inhibitors of Aurora kinases are expected to
prevent the continuous growth of cancer cells and control
abnormal mitosis. Consequently, special interest has been arisen
in developing Aurora-specific small-molecule inhibitors that block
its activity and function in targeted cancer chemotherapeutics
[18,19]. A growing number of Aurora kinase inhibitors have been
developed, including VX-680 [20], MLN8054 [21,22], and
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MLN8237 [23], TC28 [24], Hesperadin [25], ZM-447439
[26,27], PHA-680632 [28].
Although all three Aurora kinases share high sequence
similarities at the kinase domain some small differences do exist
that can be exploited for the development of such specific
inhibitors. Here we describe the development of a novel potent
Aurora A inhibitor, named Tripolin A, and report its effect on
cultured human cells. Our results indicate that Tripolin A inhibits
Aurora A kinase but not Aurora B, in mammalian cells, while it is
used to reveal a new way of regulating the function of its
substrates, i.e. by altering the distribution of HURP on spindle
MTs. Considering the plethora of pathways and the diversity of
protein complexes that Auroras participate, Tripolin A could be
used to dissect their role in interphase and mitosis.
Results
Tripolins inhibit Aurora kinase activity in vitro
A library of 105 ATP-analogues was synthesized and their
activity against Aurora A using two in vitro kinase assays was
determined. Two compounds (OXVW5 and OXVW25) showing
an inhibition greater than 70%, at a concentration of 10 mM were
further investigated and hereafter referred to as Tripolin A and
Tripolin B, respectively (Figure 1A).
The effects of increasing concentrations of ATP on the
inhibitory activity of the two compounds were examined using in
vitro kinase assays. The IC50 value of Aurora A inhibition by
Tripolin B was found to increase with increasing concentrations of
ATP present in the reaction (Figure 1B), consistent with an ATP-
competitive mode of inhibition, although the competition was
apparent only in higher concentrations of ATP (more than
200 mM). Tripolin’s A inhibition on Aurora A kinase activity
however, remained unchanged in the presence of increasing ATP
concentrations (Figure 1B), suggesting that Tripolin A acts as a
non ATP-competitive inhibitor.
Selective inhibition of Tripolins against Aurora A was
investigated using Aurora B and a panel of receptor tyrosine
kinases (Table 1). Despite the relatively limited specificity of
Tripolins for Aurora A in vitro, the fact that two similar small-
molecule compounds showed ATP competitive and non-compet-
itive mode of action prompted us to investigate them further.
We examined the relative binding strength of Tripolins to
Aurora A by performing differential scanning fluorimetry (DSF)
[29], where binding affinities are measured indirectly as a function
of the protein’s melting temperature (Tm) increment. Although
Figure 1. Tripolins inhibit Aurora kinase activity in vitro. (A) Chemical structure of Tripolin A and Tripolin B. (B) Graph showing IC50 values (in
mM) of Tripolin A (red) and Tripolin B (green) in the presence of different ATP concentrations, using an in vitro kinase assay. (C) Differential Scanning
Fluorimetry results for Aurora A in the presence and absence of the inhibitors. Blue curve determines the melting temperature of Aurora A alone
(45uC), red in the presence of Tripolin A (47uC) and green in the presence of Tripolin B (53uC).
doi:10.1371/journal.pone.0058485.g001
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both Tripolins bound Aurora A, they exhibited differential affinity
(Figure 1C). In the absence of the small-molecules the Tm of
Aurora A, determined from the protein-unfolding midpoint, was
found to be 45uC. The presence of Tripolin A induced a change of
the unfolding transition temperature (DTm) of 2uC, while the
presence of Tripolin B resulted into a much higher DTm (8uC),
apparently stabilizing better the Aurora A kinase. Since the
difference between the DTm values is related to the binding affinity
of the small-molecules, these data indicate that Tripolins recognize
different binding sites on Aurora A.
Tripolin A reduces active Aurora A kinase in vivo
Phosphorylation at Thr-288 within the activation loop (A-loop)
is necessary for Aurora A kinase activity [30]. Hence, the effect of
Tripolins on Aurora A in mammalian cells was evaluated by
immunofluorescent detection of Aurora A auto-phosphorylation
on T288.
In control (DMSO-treated) cells, pT288 was detected only in
mitotic cells and its localization was restricted on centrosomes.
Treatment of HeLa cells with 20 mM of Tripolin A for 5 h and
24 h, reduced the detected levels of pAurora A by 85% and 47%
respectively (Figure 2A, 2B). Total Aurora A bound on the spindle
was reduced by a similar percentage to pAurora A (81% and 24%
after 5 h and 24 h respectively). Treatment with the previously
reported Aurora A selective inhibitor MNL8237 [23] abolished
the levels of pAurora A after 24 h of treatment, while levels of total
Aurora A bound on the spindle were reduced by 70% (Figure S1A,
S1B).
Tripolin B treatment, however, did not affect the levels of
pAurora A in mitotic cells after 5 h of treatment, while longer
treatment (24 h) unexpectedly, increased them significantly (by
40%). Total Aurora A bound on the spindle at similar levels to
control cells (Figure 2A, 2B).
Aurora A protein levels, detected by Western blot 24 h post-
treatment, were not significantly affected upon Tripolin A or B
treatment (Figure 2C), or by MLN8237 (Figure S1C) indicating
that Aurora A is not down-regulated or degraded in the presence
of any of the compounds. Although the overall protein levels of
Aurora A remained unaltered, the spindle- bound fraction of the
protein was significantly reduced, upon Tripolin A and MLN8237
treatment, most likely due to an alteration of Aurora A
recruitment on the spindle MTs. Therefore, the decreased
pAurora A levels induced by Tripolin A indicate a reduction of
Aurora A activity in vivo and not degradation of the protein.
In order to evaluate the selectivity of Tripolins for Aurora A
over the structurally related Aurora B kinase, we performed
Western Blot and immunofluorescence for the detection of
phosphorylated Histone H3 on Ser-10, an Aurora B-specific
substrate in cells. None of the Tripolins inhibited Histone H3 S10
phosphorylation, or altered Aurora B localization (Figure 2C, 2D).
Regarding Tripolin B, the experiments in HeLa cells cannot
clarify whether binding of this compound leads to a genuine
hyperphosphorylation of Aurora A, while they come in contrast to
the in vitro results showing that Tripolin B binds and inhibits
Aurora A kinase activity (Figure 1). Therefore, it was not pursued
further in this study.
In conclusion, Tripolin A reduces the active fraction of Aurora
A on the spindle, without affecting Aurora B, indicating that
Tripolin A could act as an Aurora A inhibitor in vivo.
Tripolin A induces mitotic spindle defects and spindle
pole abnormalities
Formation of abnormal mitotic spindles is consistent with
Aurora A depletion by RNAi [21,22,31], or with treatment with
specific Aurora A inhibitors (such as MLN8054 [21,22]). The
effect of Tripolin A on spindle organization and chromosome
alignment was examined in HeLa cells by immunofluorescence.
After 5 h of treatment the effect on spindle formation and
chromosome alignment was so severe that no clear phenotype
could be distinguished (Figure 2A). After 24 h of treatment, where
partial recovery of the inhibition was observed, almost all cells
(99.3%) showed mitotic defects, that could be distinguished into
two categories: chromosome misalignment (66%), and aberrant
spindle formation, mainly tripolar (33.3%) (Figure 3A, B). The
DMSO-treated control cells displayed normal bipolar mitotic
spindles with chromosomes properly aligned along the metaphase
plate (Figure 3A, 3B). Treatment with the MNL8237 or with
siRNAs against Aurora A also caused mainly chromosome
alignment defects (56% for MLN8237 and 57% for Aurora A
RNAi) as well as aberrant spindle formation (36% for MLN8237
and 30% for Aurora A RNAi) that was not possible to count
number of poles (therefore termed disorganized) (Figure 3A, 3B,
3C).
Aurora A depletion by RNAi causes centrosome fragmentation
[32]. To examine the effect of Tripolin A on centrosomes and
spindle poles, mitotic HeLa cells were fixed 5 h or 24 h post-
treatment and stained using pericentrin and c-tubulin for
centrosomes, and Aurora A and TPX2 for spindle poles. Control
metaphase cells primarily (95%) possessed two centrosomes and
two spindle poles per cell. Almost all mitotic cells treated with
Tripolin A presented centrosome fragmentation (99% at 5 h and
98% at 24 h, Figure 3D, 3E), while Aurora A depletion by RNAi
also caused severe centrosome fragmentation (60%, Figure 3D,
3E).
In addition, Tripolin A treated cells frequently (33% after 5 h
and 25% after 24 h) formed acentrosomal spindle poles (Aurora A
and TPX2 positive, pericentrin and c-tubulin negative) forming
three or more poles per cell, with centrosomal markers being
absent/not detected in at least one of the poles (Figure 3D, 3E and
Figure S2A). Radial arrays of MTs were emanating from all
spindle poles, even the ones without centrosomal markers,
indicating nucleation not originating from centrioles. Acentroso-
mal spindle formation was also observed to a lesser extend (7%)
upon Aurora A depletion by RNAi (Figure 3C, 3D), and upon 5 h
or 24 h treatment (12% and 10% respectively) with the Aurora A
inhibitor MLN8237 (Figure S2B, S2C), while it has been reported
to occur also upon treatment with another Aurora A selective
inhibitor, the MLN8054 [22]. Since centrosome fragmentation as
well as acentrosomal pole formation was apparent 5 h and 24 h
post-treatment to a similar extend, the centrosomal abnormalities
Table 1. Selectivity of Tripolins against a panel of kinases.
IC50 values (mM)
Kinase analyzed Tripolin A Tripolin B
Aurora A 1.5 2.5
Aurora B 7.0 6.0
EGFR 11.0 71.7
FGFR 33.4 38.0
KDR 17.9 6.5
IGF1R 14.9 13.2
IC50 values of Tripolin A and Tripolin B against Aurora A, Aurora B and a panel of
other selected kinases.
doi:10.1371/journal.pone.0058485.t001
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primarily occurred due to dysfunction of Aurora A and not as a
consequence of an abnormal mitotic event in the presence of the
compounds. Therefore, we conclude that Tripolin A induces
mitotic defects specific to Aurora A inhibition.
Tripolin A influences spindle size and MT organization
Since Aurora A activation by TPX2 is required for proper
spindle length [33], we investigated the effect of Tripolin A on the
interpolar distance measured in fixed samples stained with
antibodies against a-tubulin and pericentrin. Cells treated with
Tripolin A for 24 h had shorter mean pole-to-pole distance
(7.6 mm61.3, Figure 4A, 4B) compared to control cells
(9.9 mm60.7). Lack of Aurora A interaction with TPX2, which
affects spindle-associated Aurora A but not centrosome-localized
Aurora A [2,33], has been reported to induce shorter spindles
[33]. Tripolin A affects both spindle-associated and centrosomal-
associated Aurora A (Figure 2A), therefore the shorter spindles
observed upon Tripolin A treatment are consistent with the
inhibition of the Aurora A kinase.
In order to test whether shorter spindles contained less MTs, we
quantified MT intensities on the metaphase spindles. Cells treated
with Tripolin A showed significantly increased fluorescent MT
intensity along MTs. Longitudinal line scans of MT fluorescent
intensity from metaphase spindles showed almost double MT
intensity along the length of the MTs, compared to control cells,
indicating more stable/bundled spindle MTs (Figure 4C). This
finding is consistent with a recent observation that treatment of
Figure 2. Tripolin A selectively inhibits Aurora A over Aurora B in cultured tumor cells. (A) Representative immunofluorescence images of
HeLa cells in metaphase treated with solvent control (DMSO), 20 mM Tripolin A or Tripolin B for 5 h and 24 h. In the merged images Aurora A is
pseudocolored red, pAurora T288 green, DNA blue. (Scale bars, 5 mm). (B) Fluorescence intensity (% percentage) of pAurora A T288 on centrosomes
and total Aurora A on spindles were quantified in control metaphase cells or cells treated with Tripolin A or Tripolin B (n$20 cells for each group,
from at least two independent experiments). **: 0.001,p,0.01; ***: p,0.001; ns: p.0.05; (Mann-Whitney test, two-tailed). Error bars represent SEM.
(C) Western Blot analysis for Aurora A, Aurora B and pHistone H3 Ser10 in Tripolin A and Tripolin B-treated mitotic cells. a-tubulin was used as a
loading control. (D) Representative immunofluorescence images of bipolar metaphase HeLa cells treated with solvent control (DMSO), 20 mM Tripolin
A or Tripolin B for 24 h. In the merged images pHistone H3 Ser10 is pseudocolored red, Aurora B green, DNA blue. (Scale bars, 5 mm).
doi:10.1371/journal.pone.0058485.g002
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Figure 3. Tripolin A treatment results in spindle and centrosomal defects. (A) Representative immunofluorescence images of mitotic HeLa
cells treated with DMSO, 20 mM Tripolin A for 24 h, 100 nM MLN8237 for 24 h or Aurora A siRNAs. In the merged images a-tubulin is pseudocolored
red, DNA blue. (Scale bars, 5 mm). (B) Graph showing the percentage of normal, multipolar, misaligned, disorganized and monopolar figures in control
mitotic cells (DMSO or control siRNAs) and mitotic cells treated with Tripolin A, MLN8237 or Aurora A siRNA (n = 300 cells for each group, from three
independent experiments). (C) Western Blot analysis for Aurora A levels in Aurora A siRNA treated cells. a-tubulin was used as a loading control. (D)
Images of mitotic HeLa cells treated with DMSO, 20 mM Tripolin A for 5 h and 24 h or Aurora A siRNA. In the merged images Aurora A is
pseudocolored red, pericentrin green, DNA blue. (Scale bar 5 mm). (E) Graph showing the percentage of mitotic cells with fragmented centrosomes
(up), or acentrosomal poles (down) in control mitotic cells (DMSO or control siRNA) and mitotic cells treated with Tripolin A, or Aurora A siRNA
(n = 150 cells for each group, from three independent experiments).
doi:10.1371/journal.pone.0058485.g003
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cells with the selective Aurora A inhibitor MLN8237 results in
hyperstable spindles [34].
Since it has been shown that Aurora A kinase modulates
dynamic instability of interphase MT while Aurora B does not
[35,36] we also explored the effect of Tripolin A in interphase.
Following treatment with Tripolin A, the organization of the
interphase network MT was extensively modified and presented
abnormalities that were arbitrarily classified into three categories:
disorganized, elongated/extended and bundled network
(Figure 4D). Cells treated with Tripolin A for 1 h exhibited
mainly shorter and disorganized or locally extended MT network
similarly to the MLN8237 treatment (Figure 4D, 4E) and
consistent with the effect of other Aurora A specific compounds
[35]. Longer exposure to Tripolin A (24 h) further modified the
MT network inducing more severe MT disorganization where
cells appeared to have an entirely collapsed MT array and were
classified as bundled (Figure 4D, 4E). Thus Tripolin A affects MT
dynamics both in mitosis and interphase, in a manner similar to
specific Aurora A inhibitors.
Tripolin A affects the precise localization of HURP
HURP is an Aurora A substrate [7], required for chromatin-
dependent MT nucleation, localizing preferentially to regions of
kt-MTs and affecting their stability [9,10,37].
It has been suggested that HURP’s binding on MTs is regulated
by Aurora A phosphorylation [8,12], therefore we tested the effect
of Tripolin A on HURP localization at metaphase spindles.
HURP’s binding on MTs was not significantly affected upon
Tripolin A treatment (Figure 5A, 5C). Instead, treated cells
exhibited a change in the distribution pattern of HURP on the
spindle MTs. Longitudinal line scans of HURP’s fluorescent
intensity from metaphase spindles in control-treated cells showed
maximal levels of the protein in the vicinity of chromosomes
(Figure 5A, 5B), consistent with the fact that HURP is a Ran-GTP
regulated protein [9,10,37]. In contrast, Tripolin A treated cells
Figure 4. Tripolin A alters pole-to-pole distance and MT stability in mitotic cells and influences interphase MT array. (A) Maximum
projections from z-stacks of a representative control cell and representative cells treated with Tripolin A. In the merged images a-tubulin is
pseudocolored red; pericentrin is green, DNA is blue. Yellow arrows indicate interpolar distance. (B) Interpolar distances were measured based on
pericentrin staining in HeLa cells (n$100 cells for each group, from at least three independent experiments). ***: p,0.0001; (Student’s t-test, two-
tailed). Error bars indicate SD. (C) Longitudinal line scans of tubulin intensity from metaphase spindles of control and Tripolin A treated HeLa cells
(n = 5 for each group). Intensities were normalized to the maximum value of the control curve, and spindle size was interpolated. Curves indicate
mean values. (D) Representative immunofluorescence images of HeLa cells in interphase treated with DMSO, 100 nM MLN8237 for 1 h or 20 mM
Tripolin A for 1 h and 24 h. In the merged images a-tubulin is pseudocolored red, DNA blue. (Scale bar 10 mm). (E) Graph showing the percentages of
interphase cells with altered MT array, classified in the indicated arbitrary categories in control cells (DMSO) and cells treated with MLN8237 or
Tripolin A (n = 150 cells for each group, from three independent experiments).
doi:10.1371/journal.pone.0058485.g004
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exhibited more HURP signal towards the poles. To examine the
specificity of Aurora A effect on HURP’s distribution on MTs, we
analyzed its distribution in cells treated with the selective Aurora A
inhibitor MLN8237, and in cells were spindle-associated Aurora A
was abrogated by TPX2 depletion (Figure 5A, 5B, 5D). Both
treatments caused miss-localization of HURP and loss of its
gradient MT binding towards the chromosomes. However, the
phenotypes observed upon these treatments, although similar,
were not identical to Tripolin A treatment, and this could be
attributed to the differential way they affect Aurora A activity or
localization.
Therefore, the selective binding of HURP on spindle MTs in
the vicinity of chromosomes was altered when Aurora A activity or
localization were affected. These results indicate that HURP’s
phosphorylation by Aurora A is not required for its direct binding
on the MTs, but rather for its precise localization and distribution
along spindle MTs.
Discussion
Here we describe the development and evaluation of a novel
Aurora A kinase inhibitor, named Tripolin A, as well as its effect
on certain mitotic MAPs. Although two chemically similar small-
molecules could inhibit Aurora A kinase activity in vitro, only
Tripolin A showed specific inhibition of Aurora A with no
significant effect on Aurora B, in mammalian cells.
Tripolin A treatment recapitulated phenotypes associated with
RNAi and chemical inhibition of Aurora A, including centrosome
integrity, spindle formation and length, as well as MT organization
in interphase. Additionally, Tripolin A interfered with the precise
distribution of HURP, a substrate of the Aurora A kinase, on
spindle MTs.
HURP shows a gradient localization towards the chromosomes,
which is exquisitely sensitive to RanGTP levels while it is not
affected by altered MT dynamics [10]. By using single-cell
microscopy quantification analysis we were able to evaluate
delicate alterations in protein localization that would not be
apparent using conventional population studies. It has been
suggested that HURP’s binding on MTs is regulated through
phosphorylation by Aurora A [8]. However, Aurora A depletion
by siRNA (Figure S3) or mutation of the potential Aurora A
phosphorylation residues on HURP [12], did not prevent HURP’s
binding on the MTs. Here we show that altering the levels or the
localization of Aurora A resulted in loss of the gradient localization
pattern of HURP in the proximity of the chromosomes, indicating
a spatial regulation of HURP’s distribution on the metaphase
MTs. Consistently, a GFP-fused N-terminal fragment of HURP
that lacks the C-terminus where Aurora A phosphorylation occurs,
shows a distribution closer to the spindle poles and away from the
chromosomes, resembling the effect of Tripolin A treatment (our
unpublished observations, [8,38]). Therefore it is likely that
Aurora A kinase regulates the spatial distribution of HURP on
MTs, with a positive gradient towards the chromosomes, rather
than its MT binding per se.
An understanding of the role Aurora A plays in regulating the
MT network that forms the spindle is emerging. In one model
Aurora A is critical for the regulation of the EXTAH multiprotein
complex, comprised of Eg5, XMAP215, TPX2, Aurora A, and
HURP, which have MT binding, cross-linking, and kinesin motor
activities. Together they act to bundle, cross-link, and stabilize the
growing MT network. Disruption of any component of the
complex perturbs spindle formation [9]. In this context, HURP is
affecting primarily the stability of kt-MTs [9,11], due to its
proximity to the chromosomes. Disruption of the gradient
distribution and improper localization of HURP on the spindle
poles upon Aurora A perturbation, most likely will alter MTs
Figure 5. Inhibition of Aurora A alters the localization of HURP. (A) Representative immunofluorescence images of metaphase cells treated
with DMSO, 20 mM Tripolin A or 100 nM MLN8237 for 24 h, or TPX2 siRNAs. In the merged images a-tubulin is pseudocolored red, HURP green. (Scale
bars, 5 mm). (B) Longitudinal line scans of HURP intensity from metaphase spindles of control and Tripolin A treated HeLa cells (n = 5 for each group).
Intensities were normalized to maximum value within the same spindle, and spindle size was interpolated. Curves indicate mean values. (C)
Fluorescence intensity (% percentage) of HURP quantified in control metaphase cells and cells treated with Tripolin A (n$20 cells for each group,
from at least two independent experiments). ns p.0.05; (Mann-Whitney test, two-tailed). Error bars represent SEM. (D) Western Blot analysis for TPX2,
in TPX2 siRNAs treated cells. a-tubulin was used as a loading control.
doi:10.1371/journal.pone.0058485.g005
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stability and disturb the balance which leads to proper spindle
formation.
It is interesting to note that the below treatments: a. loss of
spindle-associated Aurora A through TPX2 depletion, b. inhibi-
tion of active Aurora A by the selective inhibitor MLN8054 (our
unpublished observations) or the second-generation MLN8237, or
c. inhibition by Tripolin A, all cause loss of HURP’s gradient
distribution.
MLN8054 is a first generation ATP-competitive Aurora A
selective inhibitor, and molecular dynamics studies showed that
this selectivity is due to the induced changes in the conformation of
the activation loop of the kinase, forcing it to adopt an unusual
DFG-up conformation [39]. Tripolin A showed non-ATP
competitive mode of action in vitro. Docking analysis indicated
that it could bind and/or stabilize the inactive forms of Aurora A
either via the deep back pocket present in the DFG-out
conformation of inactive Aurora A, or with a lower probability,
via the small hydrophobic side-pocket of the DFG-up conforma-
tion (Figure S4 and Supporting Information S1). Therefore
Tripolin A could bind or stabilize a different conformation of
inactive Aurora A kinase compared to MLN8054. Taken together,
even though Tripolin A does not have a very high affinity for the
Aurora A kinase, nonetheless it has a value as a compound that
does not have preference for binding at the ATP binding pocket
and could serve as a scaffold for the development of specific and
higher affinity Aurora A inhibitors.
Small-molecule manipulation of protein kinases is a powerful
tool for studying the biological context in which they function.
When kinases are assayed in vitro in isolation from their
physiological partners, screens cannot accurately mimic the
complex environment under which these compounds function in
vivo. Considering the diversity of the pathways in which Aurora A
participates, targeting particular active or inactive DFG confor-
mations, or certain Aurora A-containing sub-complexes may in
the future become a preferable approach. Regardless of whether
such Aurora A inhibitors will succeed in cancer therapy, they
represent a potent tool to tease apart the effects of Aurora A
inhibition.
Experimental Procedures
Chemical Synthesis
General procedures. 1H and 13C NMR spectra were
recorded either on a Varian GEMINI 300 or Varian GEMINI
200 spectrometer at room temperature. Mass spectra were
measured on a Finnigan MAT MS 70 (EI) spectrometer or on a
Bruker Daltonics Apex II (ESI). Melting points are uncorrected.
Syntheses were performed as described previously [40]. Tripolin
A and Tripolin B are shown in Figure 6.
3-(2,5-Dihydroxy-benzylidene)-1,3-dihydro-indol-1-one
(Tripolin A)
Yield = 52%; mp 256uC; 1H-NMR (300 MHz, (CD3)2SO)
d=6.77–6.94 (m, 4H, 4x CHarom.); 7.10 (d,
4J=2.7 Hz, 1H,
CH= ); 7.24 (t, 4J=7.5 Hz, 1H, CHarom.); 7.64–7.70 (m, 2H, 2x
CHarom.); 9.11 (br, 1H, OH); 9.43 (br, 1H, OH); 10.58 (br, 1H,
NH); 13C-NMR ((CD3)2SO, 75.5 MHz) d=110.64, 115.52,
117.56, 119.68, 121.73 (5x CHarom.), 121.96 (Cq.), 122.20 (Cq.),
123.35 (CHarom.), 126.77 (Cq.), 130.33 (CHarom.), 133.40 (CH= ),
143.31 (Cq.), 150.12 (Cq.-OH), 150.15 (Cq.-OH), 169.66 (CO); HR-
MS (ESI, MeOH) m/z for C15H12NO3 [M+H]+: calculated:
254.08117, found: 254.08136.
3-(3H-Imidazol-4-ylmethylene)-1,3-dihydro-indol-2-one
(Tripolin B)
Yield = 88%; mp 253uC; 1H-NMR (200 MHz, (CD3)2SO)
d=6.87–7.03 (m, 2H, 2x CHarom.); 7.15–7.19 (m, 1H, CHarom.),
7.63–7.81 (m, 2H, CHarom., CH= ); 7.82 (s, 1H, CH= ); 8.01 (s,
1H, CH= ); 11.06 (br, 1H, NH); 13.73 (br, 1H, NH);
13C-NMR (50.3 MHz, (CD3)2SO) d=109.67, 119.19 (2x
CHarom.), 120,26 (Cq.), 121.37 (CHarom.), 123.42 (CH= ), 124.45
(Cq.), 127.94 (CHarom.), 129.17 (Cq.), 139.02 (CHarom.), 139.07
(CHarom.), 139.76 (Cq.), 168.75 (CO);
HR-MS (ESI, MeOH) m/z: for C12H10N3O [M+H]+: calcu-
lated: 212.08184, found: 212.08204.
Protein Expression and Purification
Aurora A full length was subcloned into the pET21d (Novagen)
vector. The recombinant Aurora A-6xHis protein was expressed in
E.coli strains and purified under non-denaturing conditions via Ni-
NTA metal affinity HiTrap Chelating HP column (Amersham
Biosciences).
In vitro kinase assays
In vitro kinase assays were performed at the Chemical facility of
the European Molecular Biology Laboratory (EMBL), as previ-
ously described [24]. The IC50 values for the different compounds
were determined by using the Luminescence ATP Detection Assay
System for Kinase Applications, Easylite-kinase (Perkin Elmer), as
well as the Z’LYTE Kinase Assay Kit-Ser/Thr 1 Peptide PV3174
(Invitrogen) by following the manufacturer’s instructions. The
ATP competition assays and the kinase selectivity profile were
assessed using the Z’LYTE Kinase Assay.
Differential Scanning Fluorimetry (DSF)/Protein Stability
Shift assay
Thermal stability experiments were carried out using the 7500
Real Time PCR System (Applied Biosystems). Aurora A-6xHis
protein (5 mM) was assayed in 20 ml of PBS1x, 150 mM NaCl,
2 mM MgCl2, 8.7% glycerol, pH 6.5 in a 96-well plate. Tripolins
Figure 6. Chemical structure of Tripolin A and Tripolin B.
doi:10.1371/journal.pone.0058485.g006
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A and B were added at a final concentration of 100 mM. SYPRO
Orange (1:1000; Invitrogen) was added as a fluoresence probe.
Appropriate excitation and emission filters for the SYPRO-
Orange dye were set. The temperature was raised at 1uC/min
from 26uC to 80uC and fluorescence readings were taken at each
interval. Data acquisition was performed using the SDS Software
version 1.4. Data analysis and plotting was performed in
GraphPad PrismH Version 5.0a software.
Cell culture, Immunofluorescence and Western Blot
analysis
HeLa cells were grown in DMEM supplemented with 10%
FBS, 2 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml
streptomycin (Invitrogen) at 37uC with 5% CO2 in a humidified
incubator. For immunofluorescence staining, cells grown on No.1
glass coverslips were fixed in 3.7% formaldehyde/PHEM (60 mM
PIPES, 25 mM Hepes, 10 mM EGTA, 2 mM MgCl2) pH 6.9 for
20 min at 37uC and then permeabilized in PBS/0.1% v/v Triton
X-100 pH 7.4 for 5 min at room temperature or were fixed/
permeabilized in 220uC methanol for 3 min. Cells were blocked
in PBS/5% w/v BSA pH 7.4 and stained with various combina-
tions of: anti-Aurora A pT288 rabbit polyclonal antibody (1:100;
Cell Signaling Technology), anti-Aurora A mouse monoclonal
antibody (1:2000; Abcam), anti-AIM-1/Aurora B mouse mono-
clonal antibody (1:500; BD Biosciences), anti-pHistoneH3 (Ser10)
rabbit polyclonal antibody (1:1000; Millipore), anti-pericentrin
rabbit polyclonal antibody (1:2000; abcam), anti-a-tubulin mouse
monoclonal antibody clone GTU-88 (1:500; Sigma-Aldrich), anti-
a-tubulin mouse monoclonal antibody (1:1000; Santa Cruz
Biotechnology), rabbit polyclonal antisera against HURP and
TPX2 [9,41], for 1 h at room temperature. Cells were washed in
PBS pH 7.4, incubated with appropriate Alexa Fluor 488 and 568
secondary antibodies (1:500; Molecular Probes) for 30 min a room
temperature and DNA was counterstained with DAPI (1 mg/ml;
AppliChem). After final washes coverslips were mounted in
homemade mowiol mounting medium.
For Western blot analysis of compound treated cells, HeLa cells
were arrested with thymidine (2 mM) for 18 h, released into fresh
medium for 6 h, and blocked with nocodazole (60 ng/ml) for
20 h. DMSO or the different compounds were added 2 h after
thymidine release. Mitotic cells were shaken off and lysed in RIPA
buffer 50 mM Tris pH 8, 150 mM NaCl, 50 mM sodium
orthovanadate, 1% v/v NP40, 0,1 mM PMSF supplemented with
complete protease inhibitors cocktail (Roche). For western blot
analysis of asynchronous treated cells (siRNA treatment), cells
were washed twice with ice cold PBS and lysed in RIPA buffer.
The protein extract for both cases (30 mg; as determined by the
Bradford assay, Bio-Rad) was loaded on SDS-PAGE, transferred
to a nitrocellulose membrane and probed with anti-Aurora A
mouse monoclonal antibody (1:1000; Abcam), anti-AIM-1/Auro-
ra B mouse monoclonal antibody (1:1000; BD Biosciences), anti-
pHistoneH3 (Ser10) rabbit polyclonal antibody (1:1000; Milli-
pore), anti-a-tubulin mouse monoclonal antibody (1:1000; Santa
Cruz Biotechnology), TPX2 [41] (1:1000).
Compound treatment and RNAi
HeLa cells were treated for 1 h, 5 h or 24 h with 20 mM
Tripolin A, 20 mM Tripolin B or 100 nM MLN8237 (SelleckBio)
diluted in DMSO while cells treated with DMSO (0.1% v/v)
served as control, unless other wise stated.
siRNAs against TPX2 59-GGGCAAAACTCCTTTGAGA-39
[33] and Aurora A
59-ATGCCCTGTCTTACTGTCA-39 [2] were purchased
from Ambion. siRNA control was also purchased from Ambion
(Silencer Negative Control #1 siRNA). 24 h hours after plating
cells were transfected with 100 nM siRNA duplexes prepared in
OptiMEM Reduced Serum Medium (Gibco) using Lipofectamine
2000 (Invitrogen). Growth medium containing transfection com-
plexes was replaced with fresh complete medium 6 hours after the
transfection. Cells were assayed 24 h post-transfection for TPX2
RNAi and 48 h post transfection for Aurora A RNAi.
Microscopy and Image analysis
Imaging of fixed samples was performed on a customized Andor
Revolution Spinning Disk Confocal System built around a stand
(IX81; Olympus) with a 100x-1.4 NA lens and a digital camera
(Andor Ixon+885) (CIBIT Facility, MBG-DUTH) or on a Zeiss
LSM780 laser scanning confocal microscope (ALMF-EMBL).
Image acquisition was performed in Andor IQ 1.10.3 software or
in Zen 2010 respectively. Optical sections were recorded every
0.3 mm.
Image intensity analysis for data sets was performed in ImageJ
1.44n (National Institute of Health, USA) software where image-
processing macros were developed. The two-dimensional (2D)
average projection of z-stack images were quantified after
background subtraction for Aurora A, TPX2, HURP a-tubulin
using a fixed size cycle area where integrated intensity values were
measured. For Aurora A, TPX2 and HURP quantification
appropriate threshold was set in order to quantify only the on
spindle signal. For pAurora A T288 intensity quantification, a
thresholding-segmentation method [42] was performed to define
centrosomal area according to pAurora A T288 signal on 2D
average projections of z-stack images and integrated intensities
were measured. Interpolar distances were measured on 2D
maximum projections of z-stack images using the analysis tools
of the image acquisition software Andor IQ 1.10.3. Statistical
Analysis and plotting was performed using the GraphPad Prism
Version 5.0a software. All microscopy images presented here are
2D maximum intensity projections of z-stack images (ImageJ
1.44n National Institute of Health, USA).
Linescans were generated after background subtraction in
average 2D projection images, by manually drawn lines (1.5
microns in thickness) from pole to pole in bipolar metaphase cells
which was marked by Aurora A or a-tubulin signal (ImageJ 1.44n
National Institute of Health, USA). X and Y values were
normalized against maximum values in the same cell, therefore,
are expressed in arbitrary units. To compare intensities of spindles
varying in size, we interpolated the data to identical length
intervals (GraphPad Prism Version 5.0a software).
Supporting Information
Figure S1 Effect of MLN8237 on Aurora A. (A) Represen-
tative immunofluorescence images of HeLa cells in metaphase,
treated with solvent control (DMSO) or 100 nM MLN8237 for
24 h. In the merged images Aurora A is pseudocolored red,
pAurora A T-288 green, DNA blue. (Scale bars 5 mm). (B)
Fluorescence intensity (% percentage) of total Aurora A on spindle
was quantified in control metaphase cells and cells treated with
MLN8237 (n$20 cells for each group, from at least two
independent experiments). ***: p,0.001; (Mann-Whitney test,
two-tailed). Error bars represent SEM. (C) Western Blot analysis
for Aurora A in control and MLN8237 treated cells. a-tubulin was
used as a loading control.
(TIF)
Figure S2 Effects of Tripolin A and MLN8237 on
centrosome organization. (A) Representative immunofluores-
cence images of HeLa cells in metaphase, treated with solvent
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control (DMSO) or 20 mM Tripolin A for 24 h. In the merged
images TPX2 is pseudocolored red, c-tubulin green, DNA blue.
(Scale bars 5 mm). (B) Images of mitotic HeLa cells treated with
solvent control (DMSO) or 100 nM MLN8237 for 5 h and 24 h.
In the merged images Aurora A is pseudocolored red, pericentrin
green, DNA blue. (Scale bar 5 mm). (C) Graphs showing the
percentage of mitotic cells with fragmented centrosomes (up), or
acentrosomal poles (down) in control mitotic cells (DMSO) and
mitotic cells treated with MLN8237 for 5 h and 24 h. (n = 150
cells for each group, from three independent experiments).
(TIF)
Figure S3 Aurora A depletion by siRNA does not affect
MT binding of HURP. Fluorescence intensity (arbitrary units)
of HURP bound on spindle MTs was quantified in control and
Aurora A depleted metaphase cells (n$20 cells for each group,
from at least two independent experiments). ***: p,0.001; ns:
p.0.05; (Mann-Whitney test, two-tailed). Error bars represent
SEM.
(TIF)
Figure S4 In silico recognition of Aurora A by Tripolin
A. Docking analysis of Tripolin A was conducted using Aurora A
crystal structures from complexes with ADP-TPX2 (DFG-in, PDB
code 1OL5), anilinopyrimidine (DFG-up, PDB code 3H10) and
quinazoline-13 (DFG-out, PDB code 2C6E), which are shown in a
wiremesh representation. Representative Tripolin A poses from
clusters with highest P-value are shown in sticks (green, best
scoring cluster; magenta, 2nd best cluster). Arrowheads: green,
ATP-binding pocket; sky-blue, deep pocket; white, putative
secondary pocket. Parts of the glycine-rich loop (Gly-loop) and
activation loop (A-loop) are also shown. Parts of protein surface
are omitted for clarity.
(TIF)
Supporting Information S1
(DOC)
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